Pathogen Inactivation of Labile Blood Products: Blood Transfusion and Histocompatibility, Page 296

Front Cover
Council of Europe
Council of Europe Publ., 2001 - Medical - 75 pages
Methods aimed at inactivation of pathogens in labile blood products have been developed in recent years. Their use raises a number of issues, including efficiency, the damage inflicted to the blood products, the toxicity for patients, and the cost-benefit ratio. In the foreseeable future, national blood transfusion services and health authorities will have to consider the introduction of these methods. The report summarises the current information on these pathogen inactivation procedures.

From inside the book

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

EXECUTIVE SUMMARY
5
OBJECTIVES
11
CLINICAL USE AND EXPERIENCE
21
Copyright

4 other sections not shown

Other editions - View all

Common terms and phrases

Bibliographic information